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ABST RACT
The gastrointestinal microbiome contains at least 100 trillion
microorganisms (bacteria, viruses, fungi), whose distribution varies from the
mouth to the rectum spatially and temporally throughout one's lifetime. The
microbiome benefits from advancing research due to its major role in human
health. Studies indicate that its functions are immunity, metabolic processes
and mucosal barrier. The disturbances of these functions, dysbiosis,
influence physiology, lead to diabetes, inflammatory bowel disease, obesity
and colon tumorigenesis. The third most common form of cancer, colorectal
cancer, is the result of many factors and genes, and although the link between
dysbiosis and this type of cancer is poorly characterized, it has been shown
that some bacterial species and their metabolites have a critical role in
developing colorectal cancer. Also, gut microbiota plays a role in the
inflammatory response and immune process perturbations during the
progression of colorectal cancer. Some new technologies, such as
metagenome sequencing, facilitated the progress by analyzing the metabolic
and genetic profile of microbiota, revealing details about the bacterial
composition, host interactions, and taxonomic alterations. This review
summarizes the studies regarding the link between gut microbiota and
colorectal cancer, targeting new therapeutic strategies.

Introduction
Dysbiosis or the alteration of the gut microbiome's
composition has recently been associated with various
human diseases, including even cancer [1]. A possible
mechanism through which the microbiota could influence
carcinogenesis is the biosynthesis of chemical carcinogens
such as N-nitroso compounds or acetaldehyde by microbes,
associated with dysbiosis-related inflammation [2]. It was
estimated that more than 70% of the human microbiome is
located in the colon, so this part of the digestive tract is
considered to be its most heavily colonized section [3]. It
may be the reason why the colon is more prone to
developing cancer, in contrast with the small intestine (the
cancer incidence is 12-fold higher in the colon compared
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to the small intestine) [4]. It is important to know that the
lifestyle and the dietary habits corroborated with other risk
factors including advanced age, impaired glucose
metabolism, pro-inflammatory states, previous therapies
such as antibiotic therapy, chemotherapy, co-morbidities
modulate the gut microbiota; that is maybe why the
microenvironment created by the alterations of the typical
resident colonic flora could be more favorable to tumor
development at this level [5-8]. Many studies report
specific alterations in the gut microbiome associated with
colorectal cancer; that is why it was taken into
consideration as a screening method, being very important
in the early diagnosis (early diagnosed patients with
colorectal cancer (stages 0, I or II), have 80% survival rates
over five years in contrast with the ones diagnosed in stage
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IV that have only a 10% survival rate). Therefore, a
promising strategy for the early diagnosis of colorectal
cancer is the detection of specific microbiome alterations
[9-13].

Discussions
1. Human microbiota
1.1 Microbial species
The human body is colonized by a complex of the
symbiotic, commensal and pathogenic microbial
community. The human microbiome does not only include
bacteria, but also fungi, protozoa and viruses [14,15]. A
comprehensive group of living organisms considered a
domain of life themselves are bacteria, many major
bacterial phyla compose the human microbiota. Among
them, the majority can be assigned to four types:
Firmicutes,
Bacteroidetes,
Actinobacteria
and
Proteobacteria [16]. Firmicutes and Bacteroidetes
represent more than 90% of the gut microbiome [17].
Firmicutes are composed mainly of Clostridia (Grampositive and anaerobic) and Bacilli (obligate or facultative
aerobics) [18,19]. Actinobacteria (for example,
Bifidobacterium) are multiple branching rods, Grampositive, non-spore-forming, non-motile and anaerobic
bacteria. The phylum Bacteroidetes is composed of nonspore, Gram-negative bacteria. Proteobacteria (for
instance, Escherichia, Klebsiella, Enterobacter) are aerobic
or facultative anaerobic, non-spore-forming rod, Gramnegative bacteria [20].
There is a concept called “enterotype clusters”, through
which the microbiota structure and different microbial
colonization are better defined in various cohorts. It also
allows the classification of each person by the relative
abundance of specific bacterial in the fecal samples. The
results of the studies performed on Japanese, American and
European subjects confirm three clusters dominated by
Bacteroides (enterotype 1), Prevotella (enterotype 2) and
Ruminococcus (enterotype 3); each one of these three types
is characterized by the relative abundance of metabolic
pathways and by specific taxonomic composition [21].
1.2 Inflammatory and immune responses
The microbiota composition varies according to the
various locations along the gastrointestinal tract. Microbial
dysbiosis can be the result of the dysregulation of the
intestinal immune system.
There is a delicate balance between the immune system
and immune-regulatory functions, because the loss of a
specific species can suppress the innate immune system or
an overreaction. There is an immunological and physical
barrier in the intestinal mucosa, between the luminal
bacteria and the underlying immune cells, called intestinal
epithelial cells; hematopoietic cells and intestinal epithelial
cells generate various receptors named pattern recognition
222

receptors; these mediate the interactions between the
commensal microbiota and the immune system [22]. Tolllike receptors and nuclear oligomerization domain-like
represent some pattern recognition receptors; these
recognize microbial molecules (microbe-associated
molecular patterns - lipid A, lipopolysaccharides, flagella,
peptidoglycans and microbial RNA/DNA) and activate
inflammasomes such as TNF alpha, cytokines and IL-1
beta [23].
It is essential to understand how and when dysbiosis
and the genetic defects in the mucosa-intestinal epithelial
cells and innate regulatory mechanisms can lead to the
development of inflammatory or infectious diseases [24].
1.3 The metabolic role
Recent studies have revealed that the gut microbiota
can generate genotoxic or metabolite stress in the intestinal
environment and thus, genetic and epigenetic changes are
facilitated and lead to cancer. As to provide the repair of
DNA damage and energy for multidrug resistance efflux
pumps, glycolysis will generate adenosine triphosphate
and nicotinamide adenine dinucleotide for the polymerase.
That is why enhanced glycolysis can have an impact on
drug resistance. Glucose metabolism can be improved by
dietary fiber that increases the abundance of Prevotella. An
increased amount of Prevotella in the gut microbiota
protects against Bacteroides induced glucose intolerance.
The last one may facilitate drug resistance and also could
affect the tumor growth. Increased glycolysis enables the
diversion of glycolytic metabolites into other important
biosynthetic pathways that play an essential role in cell
proliferation. That is why the control of gut microbiota and
their metabolites can be a useful strategy in reducing drug
resistance [25,26].
It has been shown that chronic low-grade inflammation,
promoted by lipopolysaccharides, is linked to the
occurrence of insulin resistance and obesity. These
endotoxins may cross the gut mucosa by infiltrating
chylomicrons or weak intestinal junctions, stimulating the
absorption of cholesterol and dietary triglycerides from the
gut to the plasma, producing a natural immune response.
Compared to healthy individuals, the level of circulating
endotoxins was 20% higher in people with glucose
intolerance or obesity, and 125% higher in type 2 diabetes
individuals. These elevated levels were also correlated with
high concentrations of TNF- α and IL-6 in adipocytes.
Also, a diet poor in fruit and fiber, but rich in highcarbohydrates or high-fat, triggers the systemic secretion
of lipopolysaccharides, the expression of Toll-like receptor
4, nuclear factor κB and the suppression of cytokines.
These factors regulate the pathways involved in insulin
secretion [27-30].
The microbiota plays an important role in many aspects
of the metabolism and brain functions. Several studies
reveal the importance of microbiota and micronutrients in
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attention deficit hyperactivity disorder in children.
Actinobacteria abundance may have a role in
neuropsychiatric disorders, while Bifidobacterium spp are
considered to have a protective role by several studies,
while in other studies, they seem to be key-driver [31-33].
Regarding the micronutrients, increased Copper and
Copper/zinc ratio are associated with attention deficit.
Dysbiosis and the destruction of the intestinal barrier
function was found to be a risk factor for the occurrence
and worsening of the chronic kidney disease. The
mechanisms involved are chronic inflammation and
increased productions of uremic toxins [34-37].
1.4 DNA damage
The accumulation of DNA deteriorations destabilizes
the human genome, promoting aberrant cells (pre - /
cancerous) to preserve or to accelerate mutations. Gut
microorganisms may be a serious source of DNA
mutagens. For instance, studies have proven that some
Enterococcus spp provide reactive oxygen species, such as
hydroxyl free radicals, that cause DNA alterations, point
mutations, protein-DNA crosslinking, destabilizing
colorectal
cancer-related
genes.
Enterotoxigenic
Bacteroides fragilis triggers spermine oxidase expression
on colonic epithelial cells, promoting DNA deteriorations.
Furthermore, PKS-positive Escherichia Coli stimulates
DNA double-strand breaks, cell cycle arrest and
aneuploidy cell division. All these findings prove that
microorganisms may induce DNA alterations and
destabilize the genome directly or indirectly. Thus, the gut
microbiome may be a risk factor and a treatment objective
in colorectal cancer [38].
1.5 The modulation of cell proliferation
To control the cell function and structure in normal
tissues, there are signals that control the cell's growth and
death. When perturbations of apoptotic signals and cell
proliferation develop, they will promote continued cell
proliferation,
thus
forming
malignant
tumors.
Enterotoxigenic Bacteroides fragilis drop Bacteroides
fragilis toxin (fragilysin) to promote E-cadherin cleavage,
promoting
beta-catenin
nuclear
translocation,
transcriptional upregulation of the proto-oncogene c-Myc,
and colonic cell proliferation. Identically, fusobacterium
nucleatum connects to E-cadherin through FadA,
triggering downstream pathways and promoting cell
proliferation. In conclusion, studies have proven that
dysbiosis is a cause of aberrant epithelial cell proliferation
and early tumor development [37].
2. Gut microbiota and colorectal cancer – is there any
link?
Colorectal cancer is the fourth most frequent type of
cancer worldwide, with a total of 8.5% of all new cases of
cancer/ year, thus being a major health problem [39]. The

development of this complex malignant disorder
contributes to a large amount of factors, including
environmental risk and genetic factors [40]. Considering
that less than 20% of the cases are hereditary, we can
conclude that environmental risk factors play a decisive
role, including alcohol consumption, smoking, diabetes,
obesity, a diet rich in animal fat, processed foods, red meat,
low intake of fruits and fibers [31,40]. Studies show that
genetic and epigenetic alterations in proto-oncogenes,
tumor suppressor genes and DNA repair genes, contribute
to the tumor transformation of the normal colonic
epithelium. Recently, studies have focused on gut
microbiota examination, and reported alterations in
colorectal cancer samples, indicating that the microbiome
may be a crucial factor in the induction and evolution of
colorectal cancer [41-43].
The gut microbiota contributes to the epithelial barrier
function and mucosal homeostasis, efficiently keeping
bacteria into the lumen. These function perturbations
promote an increased intestinal permeability, which is
correlated with many gastrointestinal diseases, such as
irritable bowel syndrome, celiac disease, inflammatory
bowel disease, and colorectal development. The gut
microbiota metabolic products may also influence the
immune response, activating pro-inflammatory mediators,
such as interleukin-6, cytokines, and tumor necrosis factor
– α, leading to epithelial cell damage [44]. Furthermore,
bacterial species can cause inflammatory responses or
produce toxins, thus damaging the epithelial cells directly.
Examples: species of Bacteroides fragilis and
Enterococcus faecalis generate enterotoxins and reactive
oxygen inducing oxidative DNA damage; Bacteroides
fragilis induces cellular proliferation by activating βcatenin nuclear signaling; Fusobacterium nucleatum
adheres and invades epithelial cells by the FadA surface
protein [45,46].
Studies have shown that plenty of these bacterial
species are found in different amounts in healthy
individuals compared to colorectal cancer samples. Thus,
microbiota in colorectal patients contains especially proinflammatory
opportunistic
microorganisms
and
pathogens associated with metabolic disorders, and a
reduced amount of butyrate-producing bacteria, which has
a significant role in intestinal homeostasis [47]. Moreover,
some bacterial species have a high prevalence in colorectal
patients than healthy populations: Escherichia coli,
Bacteroides fragilis, Enterococcus faecalis, Streptococcus
gallolyticus, Fusobacterium nucleatum. Instead, types of
bacteria such as Roseburia, Clostridium, Faecalibacerium
and Bifidobacterium are reduced [48]. Studies focused on
discovering oncobacteria, but no single species have been
universally detected in all colorectal patients. This
indicates that various associations of microorganisms may
223
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act synergistically, and the modifications in both damaging
or protective bacterial populations may be responsible for
the development and evolution of colorectal cancer [49].
3. Microbiome – a tool in the early diagnosis of colorectal
cancer?
The development of colorectal cancer from normal
mucosa is a complex multi-step process, from preneoplastic lesions to adenomatous polyps to carcinoma
proliferation, which may take about ten years to occur. This
is the main reason why colorectal cancer is a malignancy
that may be screened. Many countries have initiated
population screening and prevention programs, using fecal
occult blood test and the fecal immunochemical test,
followed by colonoscopy when the tests are positive. Thus,
precancerous proliferation may be detected, with a highly
successful treatment, preventing colorectal cancer and
improving the overall survival [50,51].
Current studies have focused on additional criteria that
may be considered in the algorithms used to lead patients
to colonoscopy, including molecular biomarkers connected
to the processes of carcinogenesis, such as circulating
tumor cells and cell-free DNA microRNAs, and
metabolites from plasma samples [52].
As discussed above, microbiome alterations are
associated with colorectal cancer, so the option of using
different microbiome stool signatures has emerged. Even
though there is no major difference in the overall
composition of microbiota in colorectal patients and
healthy individuals, the distinction involves plenty of key
microorganisms. This is one of the reasons why colorectal
cancer diagnosis needs to develop some specific tests for
those suggestive species, without evaluating the whole
microbiome. For example, Fusobacterium nucleatum has
been persistently discovered in large amounts in the feces
of patients with adenoma and colorectal cancer, compared
to healthy humans and cancer tissue compared to
circumferential normal tissue [53].
Even though efforts have been conducted to discover
the bacterial biomarkers that may predict the risk of
colorectal cancer, major factors such as genetics, lifestyle,
and environmental factors are known to influence the
composition of gut microbiota. Also, the quality of
samples, experimental protocols, and bioinformatics tools
are all influencing factors and may explain the differences
between studies [54]. Regardless of the advances in
bacterial signatures in colorectal cancer patients, the
clinical routine is still not using microbiome biomarkers in
the screening of colorectal cancer.
In conclusion, the purpose of all this research is finding
a superior prediction on colorectal cancer development,
evolution and treatment strategies, by incorporating
information on genetics with the microbiome, lifestyle,
environmental factors to create new risk models.
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4. Dysbiosis – a treatment target of colorectal cancer
The possibility of modulating the gut microbiome is a
new therapeutic strategy in preventing and treating some
disorders that are in direct relationship with the microbiota
alterations. Considering the possible connection between
colorectal cancer and microbiota previously mentioned,
there is an increasing interest in discovering microbiomerelated treatments. However, therapy strategies include the
use of pre- and probiotics, fecal microbiota transplantation
and phage therapy [55].
Fecal microbiota transplantation has been used as a
therapeutic method in inflammatory bowel diseases,
irritable bowel disease, metabolic syndrome, obesity,
atopy, multiple sclerosis, and favorable outcomes. There
are no conclusive data from clinical trials in treating
colorectal cancer by using fecal microbiota transplant
[56].
Another direct strategy is using antibiotics to modulate
the microbiome and indirectly influence colorectal cancer
evolution, thus targeting some bacteria (Fusobacterium
nucleatum, Bacteroides fragilis, Escherichia coli). One
study showed that the therapy reduced the amount of
Fusobacterium nucleatum and the tumor’s overall growth.
Still, antibiotics may lead to dysbiosis and drug resistance.
Therefore, there is a need for new products targeting
bacteria more specifically. For example, a glycopolymer,
antagonist of the Escherichia Coli virulence factor FimH,
exposed a reduction in bacteria's adherence to the gut
epithelia [57]. Furthermore, a low dose of a recombinant
BFT-2 enterotoxin, which is a virulence factor of
Bacteroides fragilis, reduced the tumor’s development in
the colorectal cancer mouse model [58]. Another major
factor is the interaction between the microbiome and the
viral component, and its modulation by phage therapy, due
to its role in combating antibiotic-resistant microorganisms
[59].
Another promising treatment strategy, affecting the
immune response and metabolic pathways, is diet-keeping
and vitamin D administration as an anti-neoplastic effect.
[60] It is one of the most significant factors shaping the
human microbiome, as studies have shown that alterations
induced by deoxycholic acid developed carcinogenesis. At
the same time, high dietary fiber and butyrate-producing
bacteria may considerably reduce tumor growth [61].
Studies showed that the microbiome might affect the
response of 2 cancer immunotherapeutic agents (antiCTLA4 and anti-PD-L1), by amplifying the activation of
dendritic and anti-tumor T cells responses [62-64]. Also,
the immunologic stimulation by Bacteroides spp and
Bifidobacterium spp affects the efficacy of the therapy.
Furthermore, it has been proven that the imbalance of
dietary sphingolipids may influence the effectiveness of
chemotherapy and radiotherapy [64].
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Probiotics regulate pathogenic microorganisms and the
immune response, which may reduce blood cholesterol,
colitis and prevent colorectal cancer, using different
mechanisms: releasing detoxifying agents, antiinflammatory factors, anti-carcinogenesis compounds
(anti-angiogenesis), short-chain fatty acids that increase
the intestinal barrier function [65]. For example, butyrateproducing species such as Clostridium butyricum and
Bacillus subtilis may have an anti-tumor effect;
Lactobacillus casei (strain BL23) may suppress colorectal
cancer by targeting intestinal dysbiosis [66], while
Lactobacillus casei (strain ATCC 334) produce
ferrochrome which prevents colorectal cancer evolution by
apoptosis mediated through the c-Jun N-terminal kinase
pathway [67], and Lactobacillus casei (rhamnosus Lcr35)
inhibit intestinal mucositis [68,69].
As already mentioned above, the intestinal
microbiome, through the stimulation of the immune
system, has a natural anti-carcinogenesis effect, so, it has
been suggested as a key mechanism of cancer
immunotherapy. There are three known ways: microbial
antigens activate T-cell response with activating tumorspecific immune response (Bifidobacteria spp,
Akkermansia muciniphilia, Bacteroides spp, Enterococcus
hirae), the activation of pattern recognition receptors that
mediate pro-immune and anti-inflammatory effects and the
release of small metabolites that mediate systemic effects
in the host (polyamines, vitamin, desaminotyrosine) [70].
All these data show the importance of new treatment
strategies in different types of cancer, including colorectal
cancer, meaning combined chemo- and immunotherapy
with adjuvant therapies aiming the intestinal microbiota,
such as diet, pre- and probiotics and vitamin D
supplementation [71].

Conclusions
Despite the implemented screening programs many
countries have already adopted, colorectal cancer remains
a serious public health issue, being the third leading cause
of cancer death. For this reason, research must continue to
explore new strategies regarding the prevention,
prediction, diagnosis and treatment options. Considering
the major roles gut microbiota has on metabolism, nutrition
and the immune system, as well as, tumorigenesis induced
by DNA alterations due to dysbiosis, further research is
expected to discover specific microorganisms and their
metabolites connected to colorectal cancer induction and
progression. This may provide new tools in the clinical
management of colorectal cancer patients.
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